How Syntara’s Amsulostat Delivers Lasting Relief in Tough Myelofibrosis Cases

• Phase 2a trial of amsulostat plus ruxolitinib completed with 7 patients reaching 52 weeks
• 73% of patients achieved at least 50% symptom score reduction at 24 weeks or beyond
• 44% of evaluable patients showed meaningful spleen volume reduction at 24 weeks
• No treatment-related serious adverse events reported, confirming good safety profile